MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

44.49 5

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

41.85

Max

44.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-19M

-116M

Pardavimai

670K

1M

Pelno marža

-11,216.004

Darbuotojai

437

EBITDA

-19M

-129M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+89.65% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.7B

4.3B

Ankstesnė atidarymo kaina

39.49

Ankstesnė uždarymo kaina

44.49

Naujienos nuotaikos

By Acuity

43%

57%

170 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-07 16:58; UTC

Uždarbis

BMW Trims 2025 View, Citing Weaker Performance in China

2025-10-07 23:43; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025-10-07 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025-10-07 23:19; UTC

Rinkos pokalbiai

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025-10-07 22:40; UTC

Rinkos pokalbiai

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025-10-07 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 20:44; UTC

Karštos akcijos

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025-10-07 19:42; UTC

Rinkos pokalbiai

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025-10-07 19:23; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025-10-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025-10-07 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025-10-07 15:33; UTC

Rinkos pokalbiai

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025-10-07 15:25; UTC

Rinkos pokalbiai

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025-10-07 15:15; UTC

Rinkos pokalbiai

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025-10-07 15:04; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-10-07 15:04; UTC

Rinkos pokalbiai

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025-10-07 14:52; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

89.65% į viršų

12 mėnesių prognozė

Vidutinis 80.6 USD  89.65%

Aukščiausias 143 USD

Žemiausias 40 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

15

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

170 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat